白介素12降低白血病和骨髓增生异常综合征患者外周血单个核细胞WT1基因的表达论文.docVIP

　　白介素12降低白血病和骨髓增生异常综合征患者外周血单个核细胞WT1基因的表达论文 .freels癌基因DS）的疗效。为了研究IL-12能否降低AL和MDS患者外周血单个核细胞NC）进行体外培养，在培养体系中加入IL-12。培养前和培养后第3天，用竞争性RT-PCR方法分别测定各标本中DS患者，HC-restricted cytotoxic activity of NK cells［3］ and facilitate specific allogeneic human cytotoxic T lymphocyte responses against primary leukemia cells and cell lines［4-6］ . IL-12 can potently induce IFN-γ［7，8］，and up-regulate the expression of cytotoxic ponents including perforin，serine esterase and TIA-1 in peripheral blood lymphocytes［9］. IL-12 can also stimulate continuous proliferation of both T lymphocytes and NK cells［10］. IL-12 has also been shoor activities in murine tumor models，including B16F10 melanoma，renal cell adenocarcinoma，M5076 reticulum cell sara，RARD)［13］. Subcutaneous administration of IL-12 also shoising antitumor effects in patients phoma［15］ and metastatic renal cell carcinoma［16-18］. These data suggest that IL-12 may be useful in the therapy of patients atological malignancies. The DS［22-24］. Suppression of RD in patients ia or MDS. Meanonitoring NC) from patients ia or MDS to see ination of MRD in these patients. Materials and Methods Reagents A rebinant human IL-12 (Hoffmann-La Roche Inc.，Neg，edium RPMI 1640 (Gibco) supplemented ycin，1 mmol/L L-glutamine and 10% heat-inactivated fetal bovine serum (Gibco) to yield a 100 units/ml ed consent from 5 healthy volunteers，12 patients ia (RA)，8 cases of RA yelomonocytic leukemia (CMML)］; 12 patients yeloid leukemia (AML) ［2 cases of M1，5 cases of M2，3 cases of M3，1 case of M4 and 1 case of M7 according to the French-American-British classification，5 patients in plete remission (CR)，7 in non-CR］; and 6 patients yeloid leukemia in chronic phase (CML). Patients’ profiles are summarized in Table. Their peripheral blood contained 0 to 94% of blasts. PBMNC acia Biotech，Upsala，Sl of culture medium parallel idified atmosphere containing 5% CO2 for 3 days，since our preliminary experiment shoal activation time for PBMNC cytotoxicity by IL-12 al concentrat